David Coman is the founder of Science 37. Science 37 has raised $235M in total funding. Latest round: Series D. Based in Morrisville, New York.
David Coman is the Chief Executive Officer of Science 37, a clinical research company specializing in decentralized clinical trials. He joined the company as CEO in November 2019 and led it through a public listing via a SPAC merger in May 2021 and subsequent Nasdaq debut.
Full founder directory · Investor directory · Company funding database · Fundraising library